CL Bencard

Bencard Allergie is a specialized pharmaceutical company focused on the diagnosis and treatment of allergic diseases, operating as a major subsidiary of Allergy Therapeutics. The company's heritage dates back to C.L. Bencard, a pioneer in allergen-specific immunotherapy. Bencard's product portfolio includes innovative subcutaneous and sublingual immunotherapies designed to modify the immune system's response to allergens such as pollen, dust mites, and venom. Their flagship Pollinex Quattro platform utilizes a unique combination of Microcrystalline Tyrosine (MCT) adjuvant and Monophosphoryl Lipid A (MPL) to provide ultra-short course treatment cycles. Headquartered in Munich for its German operations, the company remains a dominant player in the European allergy market.